{ "docId": "019de071-41d7-735b-bdce-76898f0847d2", "docSlug": "eaafde7daeccaea38d88b7264ade91c5", "documentTitle": "Erasca | IPO Presentation Deck | 46 slides", "authorId": "erasca", "authorName": "Erasca", "documentKindSlug": "pitchdeck", "documentKindLabel": "Pitch deck", "sourceTypeSlug": "investment_bank", "sourceTypeLabel": "Investment bank", "presentationDate": "2021-07-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 6, "pageCount": 46, "prevPage": 5, "nextPage": 7, "slideType": "team_bio", "function": "other", "density": "overcrowded", "nDataPoints": 0, "notes": "The slide highlights the credibility of the company's scientific advisors.", "elementsJson": null, "metadataConfidence": 1, "imagePath": null, "slideHref": "/slides/019de071-41d7-735b-bdce-76898f0847d2/6", "deckHref": "/decks/019de071-41d7-735b-bdce-76898f0847d2", "deckJsonHref": "/decks/019de071-41d7-735b-bdce-76898f0847d2.json", "deckAnchorHref": "/decks/019de071-41d7-735b-bdce-76898f0847d2#slide-6", "components": [ { "bbox": { "h": 0.15, "w": 0.08, "x": 0.67, "y": 0.68 }, "kind": "image", "text": "Michael Varney, PhD", "attrs": null, "subkind": "headshot", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "06c308c2-1475-4657-9603-fd7d41261def", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.15, "w": 0.08, "x": 0.03, "y": 0.445 }, "kind": "image", "text": "Stephen Blacklow, MD, PhD", "attrs": null, "subkind": "headshot", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "0fa97ab6-0ca1-4ea3-afe2-eba32cc34bae", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.15, "w": 0.08, "x": 0.03, "y": 0.165 }, "kind": "image", "text": "Kevan Shokat, PhD", "attrs": null, "subkind": "headshot", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "39dc96f6-df85-4571-949f-fd02c1904599", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.15, "w": 0.08, "x": 0.03, "y": 0.68 }, "kind": "image", "text": "Karen Cichowski", "attrs": null, "subkind": "headshot", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "46bc6534-6bbb-4a67-bd7d-4ed72dce5059", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.15, "w": 0.08, "x": 0.67, "y": 0.405 }, "kind": "image", "text": "Pablo Rodriguez-Viciana, PhD", "attrs": null, "subkind": "headshot", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "7857f17a-ec65-48be-bcec-1e6abe4d6243", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.15, "w": 0.08, "x": 0.34, "y": 0.29 }, "kind": "image", "text": "Ryan Corcoran, MD, PhD", "attrs": null, "subkind": "headshot", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "7b3e4777-b700-412c-ac46-bddc8247f394", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.15, "w": 0.08, "x": 0.34, "y": 0.57 }, "kind": "image", "text": "George Demetri, MD", "attrs": null, "subkind": "headshot", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "aad3bf25-c01d-4928-a148-9beec8fc6ae4", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.15, "w": 0.2, "x": 0.12, "y": 0.15 }, "kind": "paragraph", "text": "Kevan Shokat, PhD. Erasca co-founder; University of California, San Francisco. World expert in RAS who pioneered development of approaches to inhibit KRAS G12C (RAS-GDP) and active states of RAS (RAS-GTP)", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "20f55398-c86e-418f-b12f-96e904ebb775", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.15, "w": 0.2, "x": 0.12, "y": 0.68 }, "kind": "paragraph", "text": "Karen Cichowski. Harvard Medical School; Brigham and Women's Hospital. World expert in RAS/MAPK pathway signaling and identifying novel combination therapies to shut it down", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "7ee2cb5c-d6a8-424b-ad28-7d310ab9d3cb", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.15, "w": 0.2, "x": 0.43, "y": 0.28 }, "kind": "paragraph", "text": "Ryan Corcoran, MD, PhD. Massachusetts General Hospital Cancer Center; Harvard Medical School. World expert in ERK, having studied nearly every ERK inhibitor that has been or is being developed", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "89e059fe-fe6c-430a-a915-59910e80f6e4", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.15, "w": 0.2, "x": 0.76, "y": 0.68 }, "kind": "paragraph", "text": "Michael Varney, PhD. Former Genentech/Roche. World expert in structure-based drug design; former head of research at Agouron and former head of Genentech's Research and Early Development (gRED)", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "9782e56f-71ba-4465-9358-cbf1d4ae8827", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.15, "w": 0.2, "x": 0.12, "y": 0.45 }, "kind": "paragraph", "text": "Stephen Blacklow, MD, PhD. Harvard Medical School; Dana-Farber Cancer Institute. World expert in SHP2 who helped pioneer development of the first SHP2 inhibitor with Novartis", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "cd687abb-3d51-49cb-b848-3fc1fe2202c5", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.15, "w": 0.2, "x": 0.76, "y": 0.4 }, "kind": "paragraph", "text": "Pablo Rodriguez-Viciana, PhD. UCL Cancer Institute. World expert in RAS/MAPK pathway with focus on the SHOC2 phosphatase complex as a unique regulatory node", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "d2c14ff3-76c4-4350-a426-3bab6fd9c08f", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.15, "w": 0.2, "x": 0.43, "y": 0.57 }, "kind": "paragraph", "text": "George Demetri, MD. Dana-Farber Cancer Institute. World expert in targeted oncology therapies who pioneered the development of Gleevec, which helped launched the precision oncology revolution", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "dc93b854-6e48-40bb-bdef-a9f978257705", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.05, "w": 0.6, "x": 0.03, "y": 0.05 }, "kind": "title", "text": "SAB includes world’s leading experts in the RAS/MAPK pathway", "attrs": null, "subkind": "headline", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "96bb318b-98a8-4e65-8cdb-8f3327d92a1b", "frameworkName": null, "frameworkSlug": null } ], "metrics": [], "tools": [ { "name": "Authority citation", "slug": "authority-citation", "agent": null, "layer": "slide", "matchId": "46b4d1e8-8b44-431f-b256-b8a4eaf4ac46", "evidence": "World expert in RAS who pioneered development of approaches to inhibit KRAS G12C (RAS-GDP) and active states of RAS (RAS-GTP)", "confidence": 0.8 } ], "frameworks": [], "arcBeats": [], "loops": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }